Check out some related material

Not registered yet?

Curtis A. Hanson, MD

Professor of Laboratory Medicine and Pathology Mayo Clinic College of Medicine Rochester, Minnesota

Bob McGonnagle

Publisher, CAP TODAY

Copyright © 2019, Diaceutics. All rights reserved

REGISTER

Why should you view this webinar?
Review the role of key High Risk (HR) biomarkers in CLL, focusing on clinical evidence and raising awareness for IGHV mutation status as an important CLL biomarker that can help guide treatment decisions. Webinar will also provide best practices for how and when to request IGHV testing and how to perform testing for IGHV mutation status in CLL patients.

Objectives:
Describe testing algorithm inclusive of IGHV mutation status determination at initial diagnostic work up for all CLL patients that can support first line treatment decisions, since it is a powerful predictor of duration of response and overall survival with chemoimmunotherapy (CIT)

Show that depending upon a patient’s IGHV mutation status, alternative treatment strategies may be a more suitable option versus CIT

Demonstrate IGHV mutation status testing should be incorporated into comprehensive CLL panels with other important CLL HR prognostic and predictive markers for all newly diagnosed CLL patients

Preferable that IGHV mutation status is determined directly using a molecular method versus indirect Flow or IHC based methods that test surrogate markers.

Contributors

Recorded February 28, 2019 Thu 1:00 PM EST

IGHV Clinical Utility in CLL and Preferred Testing Practices

CAP TODAY/Diaceutics Webinar

Diaceutics has built a global data lake of diagnostic testing information, curating data from over 2500 labs around the globe. Our data analytics services, including Landscape, Tracking and Primary Market Research, leverage the diagnostic testing information to provide data-driven insights to drive seamless integration of diagnostic tests into treatment pathways.

Should IGHV status and FISH testing be performed in all CLL patients at diagnosis? A systematic review and meta-analysis
Since the first description of the natural history of chronic lymphocytic leukemia (CLL) by David Galton in 1966, the considerable heterogeneity in the disease course has been well recognized. The Rai and Binet staging systems described ∼40 years ago have proven to be robust... read on

IGHV Mutation Analysis
There are two types of Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL) - indolent and aggressive. Indolent CLL/SLL indicates the diseases is slow-growing. In these cases, doctors typically will not start treatment but rather continue to follow-up with the patient to... read on

Chronic Lymphocytic Leukemia
In this “Ask the Expert” segment, a patient asks, “What is the significance of the IGHV mutation status? When should newly diagnosed CLL patients get this test?” CLL expert Dr. Jeff Sharman, Medical Director of Hematology Research at US Oncology Network, discusses IGHV and its... read on

Less Than A Quarter of Patients With CLL Tested for IGHV Mutation Prior to Initial Therapy
Immunoglobulin heavy chain variable region (IGHV) mutation–testing, which can indicate which patients with chronic lymphocytic leukemia (CLL) have a better prognosis, is conducted among only 21% of patients treated with... read on

IGHV mutational status testing in chronic lymphocytic leukemia
As the therapeutic landscape for chronic lymphocytic leukemia (CLL) continues to expand, biological predictors of response to therapy are becoming increasingly important. One such predictive biomarker is the mutational status of the variable region of the immunoglobulin heavy chain (IGHV) gene, which is a powerful predictor of duration of response and overall survival with... read on

More about Diaceutics

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.